Krystal Biotech to Present at Upcoming Investor Conferences
Krystal Biotech (NASDAQ: KRYS) has announced its participation in two upcoming investor conferences. Chairman and CEO Krish S. Krishnan will participate in fireside chats at Citi's 2024 Global Healthcare Conference on December 3 at 8:45 am ET in Miami, Florida, and the 7th Annual Evercore HealthCONx Conference on December 4 at 2:10 pm ET in Coral Gables, Florida. Both presentations will be available via webcast on the company's website's Investors section, with recordings accessible for at least 30 days afterward.
Krystal Biotech (NASDAQ: KRYS) ha annunciato la sua partecipazione a due prossimi conferenze per investitori. Il Presidente e CEO Krish S. Krishnan parteciperà a delle conversazioni informali durante il Citi's 2024 Global Healthcare Conference il 3 dicembre alle 8:45 ora ET a Miami, Florida, e al 7th Annual Evercore HealthCONx Conference il 4 dicembre alle 14:10 ora ET a Coral Gables, Florida. Entrambe le presentazioni saranno disponibili tramite webcast nella sezione Investitori del sito web della società, con registrazioni accessibili per almeno 30 giorni dopo.
Krystal Biotech (NASDAQ: KRYS) ha anunciado su participación en dos próximas conferencias para inversores. El Presidente y CEO Krish S. Krishnan participará en charlas informales en el Citi's 2024 Global Healthcare Conference el 3 de diciembre a las 8:45 am ET en Miami, Florida, y en el 7th Annual Evercore HealthCONx Conference el 4 de diciembre a las 2:10 pm ET en Coral Gables, Florida. Ambas presentaciones estarán disponibles a través de un webcast en la sección de Inversores del sitio web de la empresa, con grabaciones accesibles durante al menos 30 días después.
크리스탈 바이오텍 (NASDAQ: KRYS)는 다가오는 두 개의 투자자 회의에 참석할 것을 발표했습니다. 회장 겸 CEO 크리쉬 S. 크리쉬난은 12월 3일 오전 8:45 ET에 플로리다주 마이애미에서 열리는 씨티의 2024 글로벌 헬스케어 컨퍼런스와 12월 4일 오후 2:10 ET에 플로리다주 코랄 게이불스에서 열리는 제7회 에버코어 헬스컨EX 컨퍼런스에서 화상 대화에 참여합니다. 두 발표 모두 회사 웹사이트의 투자자 섹션에서 웹캐스트를 통해 제공되며, 녹화본은 이후 최소 30일 동안 볼 수 있습니다.
Krystal Biotech (NASDAQ: KRYS) a annoncé sa participation à deux prochaines conférences d'investisseurs. Le Président et CEO Krish S. Krishnan participera à des discussions informelles lors de la Citi's 2024 Global Healthcare Conference le 3 décembre à 8h45 ET à Miami, en Floride, et à la 7ème Conférence annuelle Evercore HealthCONx le 4 décembre à 14h10 ET à Coral Gables, en Floride. Les deux présentations seront accessibles via webdiffusion dans la section Investisseurs du site Web de la société, avec des enregistrements disponibles pendant au moins 30 jours par la suite.
Krystal Biotech (NASDAQ: KRYS) hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen bekannt gegeben. Vorsitzender und CEO Krish S. Krishnan wird an informellen Gesprächen auf der Citi's 2024 Global Healthcare Conference am 3. Dezember um 8:45 Uhr ET in Miami, Florida, und auf der 7th Annual Evercore HealthCONx Conference am 4. Dezember um 14:10 Uhr ET in Coral Gables, Florida, teilnehmen. Beide Präsentationen werden über einen Webcast im Investorenbereich der Unternehmenswebsite verfügbar sein, mit Aufzeichnungen, die mindestens 30 Tage lang zugänglich sind.
- None.
- None.
PITTSBURGH, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in fireside chats and host investor meetings at two upcoming investor conferences:
- Citi’s 2024 Global Healthcare Conference on December 3, 2024 in Miami, Florida; fireside chat scheduled for 8:45 am ET
- 7th Annual Evercore HealthCONx Conference on December 4, 2024 in Coral Gables, Florida; fireside chat scheduled for 2:10 pm ET
Each presentation will be webcast live and may be accessed through a link on the Investors section of the Company’s website. Archived versions of the webcasts will also be available on the Investors section of the Company’s website for at least 30 days.
About Krystal Biotech, Inc.
Krystal Biotech, Inc. (NASDAQ: KRYS) is a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK® is the Company’s first commercial product, the first-ever redosable gene therapy, and the first medicine approved by the FDA for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines in respiratory, oncology, dermatology, ophthalmology, and aesthetics. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit http://www.krystalbio.com, and follow @KrystalBiotech on LinkedIn and X (formerly Twitter).
CONTACT
Investors and Media:
Stéphane Paquette
Krystal Biotech
spaquette@krystalbio.com
FAQ
When is Krystal Biotech (KRYS) presenting at Citi's 2024 Global Healthcare Conference?
What investor conferences is Krystal Biotech (KRYS) attending in December 2024?
How can investors access Krystal Biotech's (KRYS) conference presentations?
What time is Krystal Biotech's (KRYS) presentation at the Evercore HealthCONx Conference?
